Anti-PD-1-induced cardiac events in patients with melanoma

Treatment with a programmed cell death-1 receptor antagonist (anti-PD-1) in patients with malignant melanoma appears to be associated with an risk of cardiac adverse events (AEs) and increased troponin-T levels, according to findings of a study published in the European Journal of Dermatology. …